A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

计划入组 62 人 · 首次发布于 2023 年 11 月 27 日

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

计划入组 261 人 · 首次发布于 2019 年 12 月 11 日

Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer

计划入组 40 人 · 首次发布于 2015 年 9 月 4 日

GSK-2302032A

EGFR inhibitors (non-small cell lung cancer)

GFPT2 inhibitors (non-small-cell lung cancer)

ADDARIO LUNG CANCER MEDICAL INSTITUTE

United States

European Lung Cancer Working Party

Belgium

Summit Therapeutics Inc.

United States

China's NMPA Accepts Hansoh Pharmaceutical's RET Inhibitor Application for Lung Cancer Treatment

Selpercatinib Shows Sustained Long-term Efficacy in RET Fusion-Positive NSCLC Patients

Lilly's Retevmo Shows Significant Event-Free Survival Benefit in Early-Stage RET Fusion-Positive Lung Cancer